Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee
Conditions
Interventions
Fasinumab
Placebo
Locations
47
United States
Regeneron Study Site
Glendale, Arizona, United States
Regeneron Study Site
Glendale, Arizona, United States
Regeneron Study Site
Phoenix, Arizona, United States
Regeneron Study Site
Tucson, Arizona, United States
Regeneron Study Site
Anaheim, California, United States
Regeneron Study Site
Clearwater, Florida, United States
Start Date
October 15, 2018
Primary Completion Date
January 30, 2020
Completion Date
January 7, 2021
Last Updated
March 1, 2023
NCT07364578
NCT06488144
NCT07058623
NCT06083480
NCT05357378
NCT06955481
Lead Sponsor
Regeneron Pharmaceuticals
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions